Myocarditis and myasthenia gravis induced by immune checkpoint inhibitor in a patient with relapsed thymoma: A case report

Immune checkpoint inhibitors (ICIs)‐targeting CTLA4 and PD1 constitute a promising class of cancer treatment but are associated with several immune‐related adverse events (irAEs). A 55‐year‐old male patient with relapse thymoma was subjected to ICI therapy (PD‐1 antibody), 2 weeks later, the patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Peng, Zhang, Cuizhen, Guan, Hongshan, Yan, Jie, He, Mengying, Zhou, Xiaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032037/
https://www.ncbi.nlm.nih.gov/pubmed/36968348
http://dx.doi.org/10.1002/ccr3.7039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032037/
https://www.ncbi.nlm.nih.gov/pubmed/36968348
http://dx.doi.org/10.1002/ccr3.7039

Ejemplares similares